Non-Melanoma Skin Cancer Market Size, BCC & cSCC Treatment Outlook 2035

Non-Melanoma Skin Cancer Market Size & Forecast 2035

The global non-melanoma skin cancer market was valued at US$736.85 million in 2025 and is projected to reach US$1.14 billion by 2035, growing at a CAGR of 4.5% during 2026-2035. The market is being reshaped by increasing basal cell carcinoma and cutaneous squamous cell carcinoma burden, broader use of PD-1/PD-L1 inhibitors in high-risk cSCC, hedgehog pathway inhibitors in advanced BCC, photodynamic treatment expansion and demand for therapies that can reduce surgical morbidity in anatomically sensitive disease.

The most important commercial change is occurring in cutaneous squamous cell carcinoma. In October 2025, the FDA approved cemiplimab as adjuvant treatment for adults with cSCC at high risk of recurrence after surgery and radiation. The C-POST study showed a 68% reduction in the risk of recurrence or death, moving systemic immunotherapy into an earlier treatment setting rather than limiting it to unresectable or metastatic disease.

Basal cell carcinoma creates a different commercial model. Most localized BCC is treated with surgery or other lesion-directed procedures, while drug revenue is concentrated in the much smaller locally advanced and metastatic population treated with hedgehog pathway inhibitors or PD-1 therapy.

Non-Melanoma Skin Cancer Market Highlights

• 2025 Market Size: US$736.85 Million
• 2035 Market Size: US$1.14 Billion
• CAGR, 2026-2035: 4.5%
• Largest Commercial Region: North America
• North America Market Share: 40.8% in the source-year DMI analysis
• Fastest-Growing Region: Asia-Pacific
• Largest Indication: Basal Cell Carcinoma
• BCC Share of Basal and Squamous Skin Cancers: about 80% in U.S. clinical epidemiology
• cSCC Commercial Growth Catalyst: Adjuvant PD-1 immunotherapy
• Immunotherapy Share: 22.9% in the source-year treatment analysis
• Key Growth Areas: adjuvant cSCC immunotherapy, intralesional PD-1 therapy, advanced BCC sequencing, hedgehog inhibitor optimization, photodynamic therapy, nonsurgical lesion treatment and therapies for immunosuppressed patients.

The Commercial Market Is Splitting Into Localized Skin Cancer and Systemic Oncology

Non-melanoma skin cancer does not behave commercially like a conventional solid tumor market.

The majority of patients have localized BCC or cSCC that can be treated through surgical excision, Mohs micrographic surgery, curettage and electrodesiccation, cryosurgery, topical drugs, photodynamic therapy or radiation. This creates a large procedural and dermatology-care ecosystem but limits systemic drug use in routine early disease.

The pharmaceutical opportunity becomes much larger per patient when disease is locally advanced, metastatic, recurrent or classified as high risk.

In BCC, advanced treatment centers on hedgehog pathway inhibition with drugs such as vismodegib or sonidegib, followed by or replaced by cemiplimab when an HHI is unsuccessful or unsuitable.

In cSCC, checkpoint inhibition has expanded further. Cemiplimab and cosibelimab are available in advanced disease, while cemiplimab now also reaches patients in the adjuvant high-risk setting after surgery and radiation.

This produces two distinct revenue pools:

Localized NMSC drives high case volumes, dermatology visits, Mohs surgery, topical treatment, PDT, and follow-up.

High-risk and advanced NMSC drives higher pharmaceutical expenditure through checkpoint inhibitors, targeted drugs, infusion services, imaging and multidisciplinary oncology management.

For pharmaceutical and biotech buyers, the second pool carries the strongest opportunity for premium drug innovation.

Key Takeaways

• The non-melanoma skin cancer market will grow from US$736.85 million in 2025 to US$1.14 billion by 2035, at a CAGR of 4.5% during 2026-2035.
• Basal cell carcinoma dominates patient volume. American Cancer Society data indicate that close to 8 in 10 basal and squamous skin cancers are BCC, explaining the large procedural demand around excision, Mohs surgery, topical therapies and lesion-directed treatment.
• cSCC is becoming the higher-growth systemic oncology segment. The 2025 cemiplimab adjuvant approval expands immunotherapy beyond unresectable and metastatic disease into patients at high risk of recurrence after surgery and radiation.
• North America remains the largest commercial region, accounting for 40.8% of market revenue in the existing DMI analysis. Current IARC data also show Northern America carrying 52.1% of reported global NMSC incidence, supporting sustained treatment demand.
• Advanced BCC remains a targeted-therapy market. Hedgehog pathway inhibitors remain central, while cemiplimab provides a systemic option after HHI treatment or when an HHI is inappropriate.
• The competitive intensity in advanced cSCC increased materially after Sun Pharma acquired Checkpoint Therapeutics in May 2025, gaining UNLOXCYT and creating a direct onco-dermatology competitor to Regeneron's Libtayo.
• Future expansion is moving toward earlier intervention and reduced surgical burden. Phase III development now includes intralesional cemiplimab against surgery in early-stage cSCC, creating the possibility that systemic or locally delivered immunotherapy could penetrate selected lesions that are currently surgery-led.

BCC and cSCC Create Two Different Market Opportunities

Basal Cell Carcinoma: Large Patient Volume, Small Advanced-Treatment Pool

Basal cell carcinoma is the largest NMSC indication by case volume. The American Cancer Society reports that about 8 out of every 10 basal and squamous skin cancers are BCC.

This very high prevalence does not translate directly into equivalent systemic-drug revenue because most BCCs are localized and can be removed with surgery or treated through other local approaches.

NCI lists localized BCC treatments including surgical excision, Mohs surgery, radiation, curettage and electrodesiccation, cryosurgery, photodynamic therapy, topical fluorouracil and imiquimod.

The more commercially intensive population consists of patients with locally advanced or metastatic disease who cannot be managed adequately through local procedures.

Vismodegib is approved for metastatic BCC and locally advanced BCC that has recurred following surgery or cannot appropriately be treated with surgery or radiation.

Sonidegib is another Hedgehog pathway inhibitor used for locally advanced BCC in appropriate patients.

Cemiplimab addresses locally advanced or metastatic BCC following HHI treatment or when HHI therapy is not appropriate.

The commercial battle in BCC through 2035 will therefore focus less on replacing surgery across millions of simple lesions and more on advanced disease, treatment intolerance, HHI resistance and nonsurgical treatment of difficult lesions.

Cutaneous Squamous Cell Carcinoma: Smaller Case Volume but Faster Pharmaceutical Expansion

cSCC accounts for a smaller proportion of NMSC than BCC, but it generates greater systemic-treatment interest because its metastatic potential and recurrence risk are higher.

The FDA-approved cSCC immunotherapy market now includes cemiplimab and cosibelimab for advanced disease.

Cosibelimab demonstrated an objective response rate of 47% in metastatic cSCC and 48% in locally advanced cSCC in the study supporting FDA approval.

Cemiplimab's October 2025 adjuvant approval represents an even larger structural change because it creates systemic treatment demand among patients who have already undergone surgery and radiation but remain at high risk of recurrence. The C-POST study enrolled 415 patients and produced a disease-free-survival hazard ratio of 0.32 versus placebo.

The European Commission also approved adjuvant cemiplimab in November 2025, extending this treatment model across another major commercial market.

cSCC is therefore shifting from a market dominated by surgery and radiation into one with a growing perioperative and adjuvant immuno-oncology component.

Immunotherapy Is Moving Into Earlier cSCC

Adjuvant Treatment Creates a New Revenue Layer

Before 2025, checkpoint inhibitor use in cSCC was concentrated mainly in locally advanced or metastatic disease unsuitable for curative surgery or radiation.

C-POST changed that commercial boundary.

Adjuvant cemiplimab reduced the risk of disease recurrence or death by 68%, locoregional recurrence by 80% and distant recurrence by 65% versus placebo in high-risk patients after surgery and postoperative radiation.

This expands immunotherapy into a larger treatment population and creates new demand for oncology referral, infusion services and postoperative risk stratification.

Early-Stage Intralesional Treatment Could Challenge Surgery in Selected Patients

Regeneron is recruiting a Phase III trial comparing intralesional cemiplimab directly with primary surgery in early-stage cSCC.

The study is targeting 369 participants and compares lesion-directed cemiplimab with standard surgical treatment.

A successful outcome would create a very different commercial market because immunotherapy could become relevant to selected early lesions that currently generate mainly surgical revenue.

This is one of the most important pipeline developments to watch through 2030 because even modest penetration into surgery-eligible cSCC would expand the drug-treated population materially.

Advanced Basal Cell Carcinoma: Treatment Sequencing Is the Key Buying Question

The advanced BCC market is already a sequential-treatment market.

Hedgehog signaling is a central therapeutic target in BCC. Vismodegib inhibits Smoothened and is approved for metastatic or selected locally advanced disease. Sonidegib provides another HHI option.

Treatment duration can be limited by muscle spasms, taste disturbance, alopecia and other class-related adverse effects.

Research is therefore not focused only on finding another HHI. It also includes intermittent dosing and adaptive scheduling designed to maintain tumor control while improving tolerability.

A recruiting Moffitt Cancer Center study is comparing continuous and personalized intermittent vismodegib schedules in advanced BCC and has an estimated completion date in 2029.

The Phase II SONIBEC study is similarly evaluating tailored intermittent sonidegib schedules after complete response in locally advanced BCC.

For buyers, treatment persistence is therefore an important competitive metric alongside response rate.

Non-Melanoma Skin Cancer Market Drivers

Global Incidence Has Reached More Than 1.1 Million Registered Cases

IARC's GLOBOCAN 2024 data record 1,138,314 new non-melanoma skin cancer cases and 58,721 deaths worldwide. NMSC ranks fifth among cancers in the current global incidence dataset.

The registered global figure does not capture every BCC and cSCC treated in routine dermatology because reporting practices vary widely. This is particularly important in the United States, where basal and squamous skin cancers are not routinely tracked in the same way as many other invasive cancers. The American Cancer Society separately cites 5.4 million BCC and SCC diagnoses per year among 3.3 million people in the United States.

The high treatment volume supports sustained demand for dermatologists, Mohs surgeons, topical products, PDT systems, pathology and advanced-systemic treatments.

Aging Populations Increase Cumulative UV Exposure

BCC and cSCC are strongly associated with ultraviolet exposure accumulated over time. Longer life expectancy increases the number of people reaching ages in which decades of UV injury translate into clinically visible disease.

The aging effect is commercially important because older patients can develop multiple lesions and may return repeatedly for treatment.

High-Risk cSCC Creates New Systemic-Treatment Demand

Most cSCC remains curable locally, but high-risk tumors can recur or metastasize.

The adjuvant cemiplimab indication converts a portion of this population from a surgery-and-radiation market into a surgery, radiation and systemic immunotherapy market.

This increases treatment expenditure per high-risk patient and strengthens the role of medical oncology in a disease traditionally managed heavily within dermatology and surgery.

Immunosuppressed Patients Remain a High-Unmet-Need Group

Patients with organ transplantation or hematologic malignancies can face particularly difficult cSCC treatment decisions because immunotherapy may interact with underlying immune status or transplant management.

A Phase IV CosiMaster study is evaluating cosibelimab in special populations with advanced cSCC, including kidney-transplant recipients and patients with hematologic cancers.

If checkpoint inhibition can be used safely in better-defined immunosuppressed populations, the addressable systemic-treatment market could expand.

Market Restraints

Most Lesions Can Be Treated Without Expensive Systemic Drugs

The greatest restraint on pharmaceutical revenue is also a clinical advantage: most BCC and many cSCC lesions are curable through local treatment.

Surgery, Mohs surgery, curettage, cryotherapy and topical treatments remain effective for localized disease.

This limits the proportion of total NMSC patients who need high-cost targeted or immune therapy.

Treatment Cost Can Rise Rapidly Once Disease Becomes Advanced

Advanced disease requires medical oncology, infusion treatment, imaging and monitoring in addition to dermatologic care.

The difference between treating a single lesion surgically and managing recurrent or metastatic cSCC with long-duration immunotherapy creates significant variation in cost per patient and increases payer scrutiny.

Hedgehog Inhibitor Tolerability Can Limit Persistence

Vismodegib and sonidegib can cause muscle spasms, alopecia, taste changes, fatigue and other treatment-limiting adverse reactions.

This creates demand for better dosing strategies and alternative treatments but also limits continuous HHI use.

Non-Melanoma Skin Cancer Market Segment Analysis

By Indication: Basal Cell Carcinoma Generates the Largest Patient Volume

Basal cell carcinoma is the largest indication segment.

The DMI source page places BCC at roughly three-quarters of skin malignancies, while current American Cancer Society data state that around 80% of basal and squamous skin cancers are BCC.

BCC's large patient base generates strong demand for lesion-directed treatment, particularly surgery and Mohs surgery. Systemic revenue remains concentrated in advanced cases treated with vismodegib, sonidegib or cemiplimab.

The segment's future growth will increasingly depend on treatments for multiple lesions, cosmetically sensitive tumors, recurrent BCC and patients unable to tolerate prolonged HHI therapy.

Cutaneous Squamous Cell Carcinoma Is the Higher-Growth Systemic Segment

cSCC accounts for a smaller share of NMSC case volume but has become more valuable from an oncology-drug perspective.

The segment now spans three important pharmaceutical settings: locally advanced disease, metastatic disease and high-risk adjuvant therapy.

FDA approval of cosibelimab created another checkpoint inhibitor option in advanced cSCC, while the 2025 expansion of cemiplimab into adjuvant treatment increases the number of patients eligible for systemic therapy.

Pipeline studies evaluating intralesional and neoadjuvant PD-1 strategies could extend pharmaceutical treatment into still earlier disease.

By Treatment: Immunotherapy Has Become the Most Strategically Important Growth Segment

Immunotherapy held 22.9% of the market in the DMI source-year treatment analysis.

Its commercial relevance has increased substantially since that analysis.

Cemiplimab is now approved for advanced cSCC, adjuvant high-risk cSCC, and advanced BCC after or instead of HHI therapy.

Cosibelimab adds a second differentiated checkpoint inhibitor option in advanced cSCC and became commercially available in the United States under Sun Pharma in January 2026.

This makes immunotherapy the treatment segment with the strongest potential to increase revenue per treated patient.

Radiation Therapy Retains a Strong Role Where Surgery Is Difficult

Radiotherapy remains important for patients whose lesions cannot be removed surgically without significant morbidity, for selected high-risk disease, and as postoperative treatment in aggressive cSCC.

Its commercial role is particularly important in head-and-neck lesions, older patients, and tumors requiring multidisciplinary treatment.

Photodynamic Therapy Supports the Nonsurgical Market

Photodynamic therapy addresses superficial lesions and patients seeking tissue preservation or improved cosmetic outcomes.

Biofrontera continues to expand the geographic commercialization of Ameluz in Europe and identifies superficial or nodular BCC unsuitable for surgery because of morbidity or cosmetic outcome among the approved European uses.

PDT therefore occupies a commercially distinct space between topical treatment and surgery.

Chemotherapy Is Losing Strategic Importance in Advanced cSCC

Conventional chemotherapy can still have a role in selected advanced disease, but checkpoint inhibitors have materially changed systemic treatment.

The market's pharmaceutical growth is increasingly concentrated in immune and targeted therapies rather than traditional cytotoxic chemotherapy.

Regional Market Analysis

North America Combines Revenue Leadership With the World's Largest Recorded Incidence Burden

North America held 40.8% of global market revenue in the existing DMI analysis, making it the largest commercial region.

Current GLOBOCAN 2024 data strengthen the region's epidemiological importance. North America recorded 593,546 NMSC cases, representing 52.1% of globally registered incidence. Five-year prevalence reached more than 2.04 million cases and represented 54.3% of global prevalence.

The region is also at the center of treatment expansion. The United States approved adjuvant cemiplimab in October 2025 and cosibelimab for advanced cSCC in December 2024, with Sun Pharma making UNLOXCYT commercially available in January 2026.

North America will therefore remain the most important region for premium immunotherapy revenue, clinical-trial participation and early adoption of nonsurgical innovations.

Europe Combines High Incidence With Rapid Adoption of Adjuvant Immunotherapy

Europe recorded 243,221 NMSC cases in 2024, accounting for 21.4% of global incidence, and five-year prevalence exceeded 835,000 cases.

Commercial growth is supported by an aging population, high specialist dermatology utilization, and established access to surgery, radiation, and systemic oncology treatment.

The European Commission's November 2025 approval of cemiplimab as adjuvant treatment for high-risk cSCC strengthens the systemic-treatment opportunity in the region.

The region is also relevant to photodynamic therapy. Biofrontera continues to expand Ameluz distribution within Europe, including new country commercialization arrangements announced in 2025.

Asia-Pacific Is the Fastest-Growing Commercial Market

The current DMI report identifies Asia-Pacific as the fastest-growing region.

Asia recorded 123,971 registered NMSC cases in 2024, representing 10.9% of global incidence.

The commercial opportunity is supported by expanding dermatology infrastructure, larger elderly populations and growing access to oncology biologics. The regional market starts from a lower treatment-spending base than North America but has room to expand as diagnosis, pathology and specialist care improve.

Local market opportunity will vary substantially because skin type, UV exposure patterns and cancer-registration practices differ across China, Japan, India, South Korea and Southeast Asia.

Oceania Has the World's Highest Incidence Rates

Oceania accounted for 64,653 registered NMSC cases in 2024, equal to 5.7% of global incidence despite its much smaller population.

Australia stands out globally. IARC reports an age-standardized NMSC incidence rate of 169.3 per 100,000 Australian men and 111.2 per 100,000 women, the highest country rates highlighted in the current global factsheet.

Australia's 2024 country dataset records 224,864 total cancer cases versus 160,961 excluding NMSC, corresponding to 63,903 NMSC cases.

This gives Australia one of the world's most treatment-intensive NMSC environments and makes it important for dermatologic surgery, field therapy, radiation and high-risk cSCC management.

Latin America and the Caribbean Show a Larger Mortality Share Than Incidence Share

Latin America and the Caribbean recorded 84,270 cases, representing 7.4% of global incidence, but accounted for 13.8% of NMSC deaths in 2024.

The difference suggests greater unmet need in early detection, specialist referral, and access to advanced therapy.

Brazil represents the most important commercial market because of its population size and developed private oncology sector, while wider regional growth depends on dermatologist density and reimbursement for higher-cost oncology drugs.

Africa Remains an Access-Led Market

Africa accounted for 28,653 registered cases, or 2.5% of incidence, but 8.9% of global NMSC deaths.

Near-term commercial demand is therefore more strongly tied to access to pathology, surgery, and radiotherapy than to rapid uptake of premium biologics.

Country-Level Commercial Opportunity

United States: Largest Addressable Premium-Treatment Market

IARC's 2024 U.S. factsheet records 2,462,729 total cancer cases and 1,929,123 cancers excluding NMSC, corresponding to 533,606 registered NMSC cases in the dataset.

That registry-derived figure does not reflect every BCC and SCC treated clinically. The American Cancer Society cites about 5.4 million basal and squamous skin cancers diagnosed annually among 3.3 million Americans, highlighting the much larger dermatology treatment workload.

The United States is commercially important because it combines this enormous lesion volume with early access to Libtayo, UNLOXCYT, hedgehog inhibitors, Mohs surgery, and advanced clinical trials.

Australia: Highest Per-Capita Treatment Pressure

Australia recorded 63,903 NMSC cases in the 2024 IARC country totals and has the highest age-standardized incidence rates highlighted by GLOBOCAN.

Its market is dominated by very high procedural demand, repeated skin examinations, excision, and other local therapies. Advanced cSCC creates a smaller but clinically important oncology segment.

United Kingdom: Large European Treatment Population

The United Kingdom's 2024 IARC dataset lists 458,379 total cancers and 415,194 cancers excluding NMSC, corresponding to 43,185 NMSC cases.

The country's mature dermatology, oncology, and pathology infrastructure creates demand across surgery, radiation, topical treatment, and systemic therapy.

Germany: Major European Dermatology and Oncology Market

Germany recorded 566,587 total cancer cases and 528,069 cancers excluding NMSC in 2024, corresponding to 38,518 NMSC cases.

Germany's large elderly population and strong dermatology infrastructure make it particularly important for surgical and lesion-directed care as well as advanced BCC and cSCC treatment.

Canada: High NMSC Burden Supports North American Growth

Canada's 2024 IARC factsheet reports 301,741 total cancers and 241,978 cancers excluding NMSC, corresponding to 59,763 registered NMSC cases.

Canada therefore contributes materially to North America's dominant global incidence position.

Pipeline Analysis: The Most Important Assets Are Trying to Move Treatment Earlier

Intralesional Cemiplimab Could Enter Surgery-Eligible cSCC

Regeneron's Phase III study of intralesional cemiplimab is one of the most commercially significant NMSC trials because it directly compares drug treatment with primary surgery.

The study plans to enroll 369 patients with early-stage cSCC and is expected to continue through 2030.

If successful, it could establish a new lesion-directed immunotherapy category.

Neoadjuvant Cemiplimab Is Being Tested With Response-Adaptive Surgery

An NCI-supported randomized study is evaluating cemiplimab before surgery for resectable advanced cSCC and testing whether immunotherapy plus response-adapted surgery improves event-free survival compared with surgery alone.

The strategy could reduce surgical extent in selected patients and increase perioperative drug use.

Personalized Cancer Vaccines Are Entering cSCC Development

The active cSCC Phase III landscape includes development of personalized immunotherapy strategies alongside checkpoint inhibition, reflecting the search for ways to deepen response in high-risk disease.

The commercial importance lies in high-risk patients who remain vulnerable to recurrence despite surgery and radiation.

Advanced BCC Research Is Focused on Treatment Persistence

Adaptive vismodegib and tailored sonidegib schedules are being studied to reduce the treatment burden associated with continuous hedgehog inhibition.

Improved tolerability could increase treatment duration and expand the real-world value of established HHI therapy.

Photodynamic Therapy Continues to Target Superficial BCC

Late-stage clinical development remains active for BF-200 ALA/Ameluz photodynamic therapy in superficial BCC, supporting continued competition among surgery, topical drugs, and nonsurgical lesion-directed treatments.

Competitive Landscape: Onco-Dermatology Is Becoming More Concentrated

Regeneron Pharmaceuticals

Regeneron holds the strongest current position in systemic NMSC through Libtayo.

Cemiplimab spans advanced cSCC, adjuvant high-risk cSCC, and advanced BCC following or instead of HHI therapy.

The October 2025 U.S. and November 2025 EU adjuvant cSCC approvals materially widened its addressable skin-cancer population.

Regeneron is also trying to move cemiplimab earlier through intralesional and neoadjuvant development.

Sun Pharmaceutical Industries

Sun Pharma has become a much more important NMSC competitor following its US$355 million upfront acquisition of Checkpoint Therapeutics, completed in May 2025.

The transaction added UNLOXCYT (cosibelimab) to Sun Pharma's onco-dermatology portfolio.

The product became available in the United States in January 2026 for metastatic and locally advanced cSCC that cannot be treated curatively with surgery or radiation.

This gives Sun Pharma direct participation in the high-value immunotherapy segment rather than relying only on conventional dermatology products.

Roche/Genentech

Roche/Genentech remains important in advanced BCC through Erivedge (vismodegib).

Vismodegib targets Smoothened in the Hedgehog pathway and retains a defined role in locally advanced and metastatic BCC.

Its long-established clinical position makes it a benchmark for future BCC-targeted treatments.

Sun Pharma's Odomzo Portfolio Adds BCC Exposure

Sun Pharma also participates in advanced BCC through Odomzo (sonidegib), giving the company exposure to both targeted BCC therapy and immunotherapy for advanced cSCC.

That combination creates an unusually broad strategic position across the two largest NMSC indications.

Biofrontera

Biofrontera is positioned in the lesion-directed market through photodynamic therapy.

Ameluz is used in Europe for actinic keratosis and selected superficial or nodular BCC where surgery may create morbidity or poor cosmetic outcomes.

Its opportunity lies at the interface between pharmaceutical treatment and dermatologic procedures.

Merck & Co.

Pembrolizumab has established clinical activity in recurrent, metastatic and locally advanced cSCC, creating continued relevance for Merck in the broader immune-oncology competitive landscape.

Future differentiation will depend on whether combination or earlier-stage programs can create advantages against an increasingly established cemiplimab franchise.

Recent Developments Reshaping the Market

January 2026 - UNLOXCYT Becomes Commercially Available in the United States

Sun Pharma announced U.S. availability of cosibelimab for adults with metastatic or locally advanced cSCC who cannot receive curative surgery or radiation. Updated follow-up data showed objective responses in at least half of treated patients in the pivotal program.

November 2025 - European Commission Approves Adjuvant Libtayo

The European Commission approved cemiplimab for adults with cSCC at high risk of recurrence after surgery and radiation, expanding the product beyond advanced disease.

October 2025 - FDA Approves Adjuvant Cemiplimab for High-Risk cSCC

FDA approved Libtayo following C-POST, where the drug reduced the risk of recurrence or death by 68%.

May 2025 - Sun Pharma Completes Checkpoint Therapeutics Acquisition

Sun Pharma completed its acquisition of Checkpoint Therapeutics and added UNLOXCYT to its global specialty dermatology and oncology portfolio.

December 2024 - FDA Approves Cosibelimab

FDA approved cosibelimab for metastatic or locally advanced cSCC in patients who are not candidates for curative surgery or radiation. Objective response reached 47% in metastatic disease and 48% in locally advanced disease.

What Buyers Should Evaluate Before Investing in the NMSC Market

• For pharmaceutical companies, the most attractive commercial space is no longer simply "skin cancer treatment." Opportunity needs to be defined by disease setting. Advanced BCC and high-risk cSCC offer far stronger pricing and systemic-treatment potential than uncomplicated localized BCC.

• For biotechnology companies, the key question is whether a new therapy can move into surgery-eligible disease, treat checkpoint-resistant cSCC or overcome HHI intolerance and resistance in BCC.

• For hospital and oncology buyers, total treatment cost includes infusion capacity, immune-toxicity management, postoperative radiation and surveillance in addition to drug acquisition.

• For dermatology providers, adoption decisions are different. Treatment competes against Mohs surgery, excision, topical agents and PDT, making lesion clearance, cosmetic outcome, office workflow and recurrence central purchasing criteria.

• For investors, the most important distinction is between the enormous epidemiological NMSC population and the much smaller population eligible for premium systemic drugs. High incidence alone should not be interpreted as an equivalent pharmaceutical addressable market.

Non-Melanoma Skin Cancer Market Scope